Is the metabolic dysfunction-associated steatotic liver disease a predictor of chronic kidney disease?

doi:10.5527/wjn.v15.i2.118877

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 2

This Article

(19)

(18)

(0)

(26)

(297)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Nephrol. Jun 25, 2026; 15(2): 118877
Published online Jun 25, 2026. doi: 10.5527/wjn.v15.i2.118877

Table 5 Fibrosis parameters and FibroScan assessment in patients and control groups, mean ± SD/n (%)

Variables	MASLD with DM (n = 50)	MASLD without DM (n = 50)	Control group (n = 50)	P value
FIB-4	3.49 ± 1.09	2.80 ± 0.87	1.29 ± 0.40	< 0.001
APRI	1.55 ± 0.29	1.41 ± 0.34	1.04 ± 0.39	< 0.001
FibroScan score	13.01 ± 3.49	10.69 ± 5.44	4.76 ± 0.27	< 0.001
Degree of fibrosis				0.001
F0	5 (10)	13 (26)	45 (90)
F1	9 (18)	20 (40)	5 (10)
F2	11 (22)	10 (20)	0
F3	12 (24)	5 (10)	0
F4	13 (26)	2 (4)	0
Steatosis score	282.11 ± 45.67	208.33 ± 55.90	178.09 ± 23.10	< 0.001
Degree of steatosis				0.010
S0	3 (6)	8 (16)	39 (78)
S1	11 (22)	13 (26)	11 (22)
S2	15 (30)	13 (26)	0
S3	21 (22)	16 (32)	0

APRI: Aspartate aminotransferase to platelet ratio index; FIB-4: Fibrosis-4 index; MASLD: Metabolic dysfunction-associated steatotic liver disease; DM: Diabetes mellitus; F: Fibrosis; S: Steatosis.

Full Size Table

Citation: Azoz NM, Shehata MA, Abbas WA, Gadelkareem RA, Abdel Aziz EM. Is the metabolic dysfunction-associated steatotic liver disease a predictor of chronic kidney disease? World J Nephrol 2026; 15(2): 118877
URL: https://www.wjgnet.com/2220-6124/full/v15/i2/118877.htm
DOI: https://dx.doi.org/10.5527/wjn.v15.i2.118877

Azoz NM, Shehata MA, Abbas WA, Gadelkareem RA, Abdel Aziz EM. Is the metabolic dysfunction-associated steatotic liver disease a predictor of chronic kidney disease? World J Nephrol 2026; 15(2): 118877 [PMID: 42395676 DOI: 10.5527/wjn.v15.i2.118877]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.